Difference between revisions of "Part:BBa K2686000"
(→Expression) |
(→Expression) |
||
Line 25: | Line 25: | ||
A cell free expression system was used to synthesize the encapsulin proteins ''in vitro''. The TX-TL cell free system is a robust way to express proteins (Sun et al., 2013), and was used by last year's EPFL iGEM team [[2017.igem.org/Team:EPFL/Description/Lysates| Aptasense]]. | A cell free expression system was used to synthesize the encapsulin proteins ''in vitro''. The TX-TL cell free system is a robust way to express proteins (Sun et al., 2013), and was used by last year's EPFL iGEM team [[2017.igem.org/Team:EPFL/Description/Lysates| Aptasense]]. | ||
− | [[File:SDS LysBodipy.tiff|thumb|center|upright=3|SDS PAGE of encapsulins expressed in cell free TX-TL system with Lysine-BODIPY fluorescent tRNA's. The two different sets of lanes correspond to different heat denaturation temperatures (70C and 100C for 15 minutes). From left to right: '''N''' Negative control (cell-free PURE expression without DNA and no purification), '''L''' Positive control with DNA coding for Luciferase (37kDa), '''H''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) showing bands for the encapsulin multimer high on the gel lanes as well as the monomer around 31kDa, '''R''' Encapsulin ([[parts.igem.org/Part:BBa_K2686001|BBa_K2686001]]) without HexaHis linker, '''N''' Negative control (cell-free PURE expression without DNA and 100C denaturation), '''Ladder''', '''L''' Positive control with DNA coding for Luciferase (37kDa), '''H''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) showing bands for the encapsulin multimer high on the gel lanes as well as the monomer around 31kDa, '''R''' Encapsulin ([[parts.igem.org/Part:BBa_K2686001|BBa_K2686001]]) without HexaHis linker, '''N''' Negative control (cell-free PURE expression without DNA and 70C denaturation)]] | + | [[File:SDS LysBodipy.tiff|thumb|center|upright=3|SDS PAGE of encapsulins expressed in cell free TX-TL system with Lysine-BODIPY fluorescent tRNA's. The two different sets of lanes correspond to different heat denaturation temperatures (70C and 100C for 15 minutes). From left to right: '''N''' Negative control (cell-free PURE expression without DNA and no purification), '''L''' Positive control with DNA coding for Luciferase (37kDa), '''H''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) showing bands for the encapsulin multimer high on the gel lanes as well as the monomer around 31kDa, '''R''' Encapsulin ([[parts.igem.org/Part:BBa_K2686001|BBa_K2686001]]) without HexaHis linker, '''N''' Negative control (cell-free PURE expression without DNA and 100C denaturation), '''Ladder''' LC5928 BenchMark™ Fluorescent Protein Standard |
+ | , '''L''' Positive control with DNA coding for Luciferase (37kDa), '''H''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) showing bands for the encapsulin multimer high on the gel lanes as well as the monomer around 31kDa, '''R''' Encapsulin ([[parts.igem.org/Part:BBa_K2686001|BBa_K2686001]]) without HexaHis linker, '''N''' Negative control (cell-free PURE expression without DNA and 70C denaturation)]] | ||
[[File:Encapsulin SDS1.png|thumb|center|upright=3|SDS PAGE of the different encapsulin proteins expressed by iGEM EPFL 2018. Cell-free mixture '''Before''' ('''B''') heat purification procedure outlined above, the '''pellet''' after the heat purification procedure ('''P''') and the '''supernatant''' after the heat purification procedure ('''S'''). '''Triangles''' <nowiki>▲</nowiki> signify the location of encapsulin 60-mer bands to the right, whereas '''stars''' <nowiki>✦</nowiki> show encapsulin monomer bands to their right. | [[File:Encapsulin SDS1.png|thumb|center|upright=3|SDS PAGE of the different encapsulin proteins expressed by iGEM EPFL 2018. Cell-free mixture '''Before''' ('''B''') heat purification procedure outlined above, the '''pellet''' after the heat purification procedure ('''P''') and the '''supernatant''' after the heat purification procedure ('''S'''). '''Triangles''' <nowiki>▲</nowiki> signify the location of encapsulin 60-mer bands to the right, whereas '''stars''' <nowiki>✦</nowiki> show encapsulin monomer bands to their right. | ||
From left to right: '''1-3''' Negative control (cell-free TX-TL expression without DNA), '''4-6''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) showing bands for the encapsulin multimer high on the gel lanes as well as the monomer around 31kDa, '''7''' HexaHis-OVA Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686000]]) where bands are not easily discernible, '''8''' Ladder, '''9''' HexaHis-OVA Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686000]]) where the monomer band is visible at 31kDa, '''10-12''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) where the bands for the 60-mer and monomer can be identified, '''13-15''' HexaHis-OVA Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686000]])]] | From left to right: '''1-3''' Negative control (cell-free TX-TL expression without DNA), '''4-6''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) showing bands for the encapsulin multimer high on the gel lanes as well as the monomer around 31kDa, '''7''' HexaHis-OVA Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686000]]) where bands are not easily discernible, '''8''' Ladder, '''9''' HexaHis-OVA Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686000]]) where the monomer band is visible at 31kDa, '''10-12''' HexaHis Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686002]]) where the bands for the 60-mer and monomer can be identified, '''13-15''' HexaHis-OVA Encapsulin ([[parts.igem.org/Part:BBa_K2686002|BBa_K2686000]])]] | ||
+ | |||
+ | [[File:NativeGel.png|thumb|center|upright=3|Native PAGE gel of sfGFP, HexaHis-OVA Encapsulin and HexaHis-OVA Encapsulin sfGFP-tag. '''Before''' ('''B''') heat purification procedure outlined in '''Purification''' section, '''Supernatant''' ('''S''') after the heat purification procedure]] | ||
===Purification=== | ===Purification=== |
Revision as of 08:50, 16 October 2018
Encapsulin with HexaHistidine insert and C-terminal OT1
This part encodes a modified Thermotoga maritima Encapsulin protein. The part is optimized for expression in E. coli and has an additional HexaHistidine (GGGGGGHHHHHHGGGGG) insert between amino acids 43 and 44, forming a loop on the interior surface of the encapsulin monomer providing higher heat resistance and stability, and better hydrodynamic properties (Moon et al., 2014). The C-terminus of the encapsulin is fused to a SIINFEKL (OVA) peptide which is displayed on the exterior surface of the encapsulin monomer as an antigen (Choi et al., 2016). SIINFEKL was chosen as it is a very popular model antigen sequence in research and a variety of antibodies targeting it are available, furthermore it is used as a tumor antigen model in scientific research and has been used in conjunction with encapsulin (Choi et al., 2016).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 77
Illegal BglII site found at 492 - 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 426
Illegal SapI.rc site found at 457
Characterization
A variety of different characterization techniques were used to assess the properties of the encapsulin protein cage.
Expression
A cell free expression system was used to synthesize the encapsulin proteins in vitro. The TX-TL cell free system is a robust way to express proteins (Sun et al., 2013), and was used by last year's EPFL iGEM team Aptasense.
Purification
After having tested a variety of purification procedures, heat purification at 70C for 20 minutes followed by cooling on ice for 15 minutes and a subsequent centrifugation at 12000g for 10 minutes was found to be the most efficient way of isolating the encapsulin (encapsulin ends up in supernatant).
Assembly
The self assembly of the encapsulin 60-mer was first examined using SDS PAGE, where a high band is expected to form due to the high molecular weight and size of the 1.3MDa complex.
References
Choi, B., Moon, H., Hong, S., Shin, C., Do, Y., Ryu, S. and Kang, S. (2016). Effective Delivery of Antigen–Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection. ACS Nano, 10(8), pp.7339-7350.
Moon, H., Lee, J., Min, J. and Kang, S. (2014). Developing Genetically Engineered Encapsulin Protein Cage Nanoparticles as a Targeted Delivery Nanoplatform. Biomacromolecules, 15(10), pp.3794-3801.
Shimizu, Y., Inoue, A., Tomari, Y., Suzuki, T., Yokogawa, T., Nishikawa, K. and Ueda, T. (2001). Cell-free translation reconstituted with purified components. Nature Biotechnology, 19(8), pp.751-755.
Sun, Z., Hayes, C., Shin, J., Caschera, F., Murray, R. and Noireaux, V. (2013). Protocols for Implementing an Escherichia coli Based TX-TL Cell-Free Expression System for Synthetic Biology. Journal of Visualized Experiments, (79).